U.S. Department of Health and Human Services
Jürgen Wess
 

 Contact Info

 
Tel: 301-402-3589
Email: jurgenw@helix.nih.gov
 

 Select Experience

 
  • ChiefMolecular Signaling Section, Laboratory of Biological Chemistry, NIDDK, NIH1998
  • HeadG Protein-Coupled Receptor Unit, NIDDK, NIH1993-1997
  • HeadG Protein-Coupled Receptor Unit, NINDS, NIH1991-1993
  • Postdoctoral FellowJoint Appointment at NIMH and NINDS, NIH1988-1991
  • Ph.D.Johann Wolfgang-Goethe University1987
 

 Related Links

 

    Jürgen Wess, Ph.D.

    Senior Investigator, Laboratory of Bioorganic ChemistryMolecular Signaling Section
    Specialties
    • Cell Biology/Cell Signaling
    • Molecular Biology/Biochemistry
    • Molecular Pharmacology/Toxicology

    ​Research Images

    Images or videos appear below. Clicking images or videos provides an expanded view.

    TitleDescriptionImage
    Molecular models of four distinct dimeric arrangements of the M3 muscarinic receptorThe structures shown here represent four distinct low-energy M3 muscarinic receptor dimers that are compatible with experimental BRET data (McMillin SM, et al. J. Biol. Chem. 286, 28584-8, 2011).Molecular models of four distinct dimeric arrangements of the M3 muscarinic receptorEnlarge
    High-resolution X-ray structure of the M3 muscarinic receptor (M3R)(A) Overall structure of the M3R bound to tiotropium, a muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease and (B) an extracellular view of the tiotropium binding site (Kruse AC, et al. Nature 482, 552-6, 2012).High-resolution X-ray structure of the M3 muscarinic receptor (M3R)Enlarge
    Schematic representation of CNO-sensitive designer GPCRs (DREADDs)All depicted DREADDs contain the Y3.33C and A5.46G point mutations in TM3 and TM5, respectively (indicated by the red 'x marks').  The resulting designer receptors are unable to bind acetylcholine (ACh), the endogenous muscarinic receptor agonist, but can be activated by CNO with high potency and efficacy.  CNO is a pharmacologically inactive metabolite of clozapine.  Depicted are (B) DREADDs differing in their G protein coupling properties (Armbruster BN, et al. Proc. Natl. Acad. Sci. U.S.A. 104, 5163-8, 2007; Guettier JM, et al. Proc. Natl. Acad. Sci. U.S.A. 106, 19197-19202, 2009) and (C) the structure of an arrestin-biased DREADD (Nakajima KI and Wess J. Mol. Pharmacol. 82, 575-82, 2012).Schematic representation of CNO-sensitive designer GPCRs (DREADDs)Enlarge
    Wess Photo Lab Members(From left to right): Kelly Hu, Yinghong Cui, Derek Bone, Sally McMillin, Shalini Jain, Jürgen Wess, Mario Rossi, Ken-ichiro Nakajima, Wataru Sakamoto, and Jianxin HuWess Photo Lab MembersEnlarge